


In the Claims:


1. – 52. (Cancelled)

53. (Previously Presented) A composition comprising a polyethylenimine or a salt thereof, wherein said polyethylenimine is represented by formula (VI):




wherein R_1 represents hydrogen or a tosyl group; and R_2 represents $C_{16}H_{33}$, $C_{12}H_{25}$ or C_8H_{17} .

54. (Previously Presented) A composition comprising a polyethylenimine or a salt thereof, wherein said polyethylenimine is represented by formula (VII):




wherein R_1 represents hydrogen or a tosyl group; and R_2 represents $C_{16}H_{33}$, $C_{12}H_{25}$, C_8H_{17} , or C_4H_9 .

55. (Previously Presented) A composition comprising a polyethylenimine or a salt thereof, wherein said polyethylenimine is represented by formula (VIII):



wherein R₁ represents hydrogen or a tosyl group; and R₂ represents a hydroxyl group, bromide, or (CH₃)₃C(CH₃)₂SiO.

56. (Previously Presented) A composition comprising a polyethylenimine or a salt thereof, wherein said polyethylenimine is represented by formula (IX):



wherein R₁ represents hydrogen or a tosyl group; and R₂ represents C₁₆H₃₃.

57. (Currently Amended) The composition of any one of Claims 53 ~~54~~ to 56, further comprising a phospholipid.

58. (Previously Presented) The composition of Claim 57, wherein the phospholipid is a neutral or basic phospholipid.

59. (Previously Presented) The composition of Claim 58, wherein the phospholipid comprises a phosphatidylethanolamine or phosphatidylcholine skeleton.

60. (Previously Presented) The composition of Claim 58, wherein the phospholipid is a diolelphosphatidylethanolamine or phosphatidylcholine.

61. (Currently Amended) A complex comprising a physiologically active substance comprising a negative charge and a composition of any one of Claims 53 ~~54~~ to 56.

62. (Previously Presented) The complex of Claim 61, wherein the physiologically active substance comprising a negative charge is a nucleic acid or its derivative.

63. (Previously Presented) A method for introducing a physiologically active substance comprising a negative charge to a cell, said method comprising a step of contacting the complex of Claim 61 with said cell.

64. (Previously Presented) A composition comprising a polyalkylenimine or a salt thereof, wherein said polyalkylenimine or said salt comprises (i) two or more tetraethylenepentamine or spermine structures, and (ii) two or more hydrophobic groups, wherein said polyalkylenimine has a degree of alkylation of less than or equal to 24.5%.

65. (Previously Presented) The composition of claim 64, wherein said polyalkylenimine or said salt comprises two or more tetraethylenepentamine structures.

66. (Previously Presented) The composition of claim 64, wherein said polyalkylenimine or said salt comprises two or more spermine structures.

67. (Previously Presented) The composition of claim 64, wherein the hydrophobic group is a cholesterol residue, a saturated or unsaturated alkyl group, a saturated or unsaturated acyl group, a saturated or unsaturated acyloxycarbonyl group, or a phospholipid residue.

68. (Previously Presented) The composition of claim 64, wherein the hydrophobic group is an octyl group, a cetyl group, a stearyl group, or an oleyl group.

69. (Previously Presented) The composition of claim 64, wherein the molecular weight of said polyalkylenimine or said salt is less than or equal to 1,000,000.

70. (Previously Presented) The composition of claim 64, wherein the molecular weight of said polyalkylenimine or said salt is less than or equal to 500,000.

71. (Previously Presented) The composition of claim 64, wherein the molecular weight of said polyalkylenimine or said salt is 500 to 100,000.

72. (Previously Presented) The composition of claim 64, wherein two to five molecules of tetraethylenepentamine are linked in a linear manner.

73. (Previously Presented) The composition of claim 64, wherein two to five molecules of spermine are linked in a linear manner.

74. (Previously Presented) The composition of claim 64, further comprising a phospholipid.

75. (Previously Presented) The composition of claim 74, wherein the phospholipid is a neutral or basic phospholipid.

76. (Previously Presented) The composition of claim 74, wherein the phospholipid comprises a phosphatidylethanolamine or phosphatidylcholine skeleton.

77. (Previously Presented) The composition of claim 74, wherein the phospholipid is a dioleylephosphatidylethanolamine or phosphatidylcholine.

78. (Previously Presented) A complex comprising a physiologically active substance comprising a negative charge and the composition of claims 64.

79. (Previously Presented) The complex of claim 78, wherein said physiologically active substance comprising a negative charge is a nucleic acid or its derivative.

80. (Previously Presented) A method for introducing a physiologically active substance comprising a negative charge to a cell, said method comprising a step of contacting the complex of claim 78 with said cell.

81. (Previously Presented) A kit for preparing the composition of claim 74, comprising (a) a phospholipid, and (b) a polyalkylenimine or a salt thereof, wherein said

polyalkylenimine or said salt comprises (i) two or more tetraethylenepentamine or spermine structures, and (ii) two or more hydrophobic groups.

82. (New) The composition of claim 64, wherein said polyalkylenimine is polyethylenimine having an average molecular weight of about 600 Da.

83. (New) The composition of claim 82, wherein said two or more hydrophobic groups are selected from $C_{10}H_{21}$, $C_{12}H_{25}$, $C_{14}H_{29}$, $C_{16}H_{33}$, and $C_{18}H_{37}$.

84. (New) The composition of claim 64, wherein said polyalkylenimine is polyethylenimine having an average molecular weight of about 1800 Da.

85. (New) The composition of claim 84, wherein said two or more hydrophobic groups are $C_{16}H_{33}$.